by admin | Nov 26, 2025 | press-releases-rss
This post was originally published on this site.– Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors – IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...
by admin | Nov 25, 2025 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...
by admin | Nov 14, 2025 | press-releases-rss
This post was originally published on this site.Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued...
by admin | Sep 5, 2025 | press-releases-rss
This post was originally published on this site.– Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin...
by admin | Sep 3, 2025 | press-releases-rss
This post was originally published on this site.– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of...
by admin | Aug 29, 2025 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...